Dake Benjamin T's Form 4 filing
Jade Biosciences, Inc. (JBIO) · filed Dec 8, 2022
- Accession no.
- 0001415889-22-012273
- Filed
- Dec 8, 2022
- Trade date
- Dec 6, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 4 derivative transactions. Open-market sales total $706.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dake Benjamin TCIK 0001869248 | Officer (SEE REMARKS) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2022 | Common Stock | MOption exerciseAcquired | +2,412 | $1.74 | +$4,196.88 | 2,412 | Direct | |
| Dec 6, 2022 | Common Stock | MOption exerciseAcquired | +37,588 | $2.14 | +$80,438.32 | 40,000 | Direct | |
| Dec 6, 2022 | Common Stock | SSaleDisposed | −2,011 | $15.61F2 | −$31,391.71 | 37,989 | Direct | |
| Dec 6, 2022 | Common Stock | SSaleDisposed | −1,259 | $16.90F3 | −$21,277.1 | 36,730 | Direct | |
| Dec 6, 2022 | Common Stock | SSaleDisposed | −36,115 | $17.80F4 | −$642,847 | 615 | Direct | |
| Dec 6, 2022 | Common Stock | SSaleDisposed | −615 | $18.29F5 | −$11,248.35 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 6, 2022 | Common Stock | MOption exerciseDisposed | −906 | $0.00 | $0 | 11,772 | Direct | |
| Dec 6, 2022 | Common Stock | MOption exerciseDisposed | −1,507 | $0.00 | $0 | 30,136 | Direct | |
| Dec 6, 2022 | Common Stock | MOption exerciseDisposed | −1,018 | $0.00 | $0 | 28,515 | Direct | |
| Dec 6, 2022 | Common Stock | MOption exerciseDisposed | −36,570 | $0.00 | $0 | 218,030 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.152 to $15.98, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.19 to $17.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.191 to $18.16, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
- F5
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.192 to $18.33, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Referenced by the price of 1 transaction in Table I.
Remarks
Officer Title: President, Chief Operating Officer and Secretary